ID

36400

Beschreibung

Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pattern of Use and ORR; ODM derived from: https://clinicaltrials.gov/show/NCT02322736

Link

https://clinicaltrials.gov/show/NCT02322736

Stichworte

  1. 10.05.19 10.05.19 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

10. Mai 2019

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Metastatic Colorectal Cancer NCT02322736

Eligibility Metastatic Colorectal Cancer NCT02322736

Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
adult patient (age ≥18 years) at enrollment
Beschreibung

Adult | Age

Datentyp

boolean

Alias
UMLS CUI [1]
C0001675
UMLS CUI [2]
C0001779
histological documentation of mcrc diagnosis
Beschreibung

Colorectal cancer metastatic

Datentyp

boolean

Alias
UMLS CUI [1]
C0948380
ras wt tumor documented before study enrolment as per routine laboratory finding
Beschreibung

Neoplasm RAS Wild Type Laboratory Procedure

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0027651
UMLS CUI [1,2]
C4331207
UMLS CUI [1,3]
C0022885
subjects whose care will be managed primarily by the enrolling physician and/or all records will be available
Beschreibung

Patient care Enrollment Physician

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0017313
UMLS CUI [1,2]
C1516879
UMLS CUI [1,3]
C0031831
measurable disease at baseline (preferably according to the response evaluation criteria in solid tumors version 1.1 (recist v1.1) if routinely used)
Beschreibung

Measurable Disease

Datentyp

boolean

Alias
UMLS CUI [1]
C1513041
currently under (begin up to 8 weeks before informed consent) a 1st or 2nd line treatment regimen, including vectibix® as per indication
Beschreibung

First line treatment | Second line treatment | Indication Vectibix

Datentyp

boolean

Alias
UMLS CUI [1]
C1708063
UMLS CUI [2]
C1710038
UMLS CUI [3,1]
C3146298
UMLS CUI [3,2]
C1743549
tumor assessment (i.e. ct/mri) within 12 weeks prior to first vectibix® infusion
Beschreibung

Neoplasm Assessment CT | Neoplasm Assessment MRI | Status pre- Vectibix Infusion

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0027651
UMLS CUI [1,2]
C1516048
UMLS CUI [1,3]
C0040405
UMLS CUI [2,1]
C0027651
UMLS CUI [2,2]
C1516048
UMLS CUI [2,3]
C0024485
UMLS CUI [3,1]
C0332152
UMLS CUI [3,2]
C1743549
UMLS CUI [3,3]
C1827465
signed informed consent
Beschreibung

Informed Consent

Datentyp

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
participation in any interventional clinical study (currently or during the three previous months from enrollment).
Beschreibung

Study Subject Participation Status | Interventional Study

Datentyp

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C3274035
compromised ability to give informed consent (defined per clinical judgment).
Beschreibung

Ability Limited Informed Consent

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0085732
UMLS CUI [1,2]
C0439801
UMLS CUI [1,3]
C0021430
unknown or mutant ras tumor type
Beschreibung

Tumor type Unknown | Tumor type Mutant RAS

Datentyp

boolean

Alias
UMLS CUI [1,1]
C4263544
UMLS CUI [1,2]
C0439673
UMLS CUI [2,1]
C4263544
UMLS CUI [2,2]
C4331205

Ähnliche Modelle

Eligibility Metastatic Colorectal Cancer NCT02322736

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Adult | Age
Item
adult patient (age ≥18 years) at enrollment
boolean
C0001675 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Colorectal cancer metastatic
Item
histological documentation of mcrc diagnosis
boolean
C0948380 (UMLS CUI [1])
Neoplasm RAS Wild Type Laboratory Procedure
Item
ras wt tumor documented before study enrolment as per routine laboratory finding
boolean
C0027651 (UMLS CUI [1,1])
C4331207 (UMLS CUI [1,2])
C0022885 (UMLS CUI [1,3])
Patient care Enrollment Physician
Item
subjects whose care will be managed primarily by the enrolling physician and/or all records will be available
boolean
C0017313 (UMLS CUI [1,1])
C1516879 (UMLS CUI [1,2])
C0031831 (UMLS CUI [1,3])
Measurable Disease
Item
measurable disease at baseline (preferably according to the response evaluation criteria in solid tumors version 1.1 (recist v1.1) if routinely used)
boolean
C1513041 (UMLS CUI [1])
First line treatment | Second line treatment | Indication Vectibix
Item
currently under (begin up to 8 weeks before informed consent) a 1st or 2nd line treatment regimen, including vectibix® as per indication
boolean
C1708063 (UMLS CUI [1])
C1710038 (UMLS CUI [2])
C3146298 (UMLS CUI [3,1])
C1743549 (UMLS CUI [3,2])
Neoplasm Assessment CT | Neoplasm Assessment MRI | Status pre- Vectibix Infusion
Item
tumor assessment (i.e. ct/mri) within 12 weeks prior to first vectibix® infusion
boolean
C0027651 (UMLS CUI [1,1])
C1516048 (UMLS CUI [1,2])
C0040405 (UMLS CUI [1,3])
C0027651 (UMLS CUI [2,1])
C1516048 (UMLS CUI [2,2])
C0024485 (UMLS CUI [2,3])
C0332152 (UMLS CUI [3,1])
C1743549 (UMLS CUI [3,2])
C1827465 (UMLS CUI [3,3])
Informed Consent
Item
signed informed consent
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Study Subject Participation Status | Interventional Study
Item
participation in any interventional clinical study (currently or during the three previous months from enrollment).
boolean
C2348568 (UMLS CUI [1])
C3274035 (UMLS CUI [2])
Ability Limited Informed Consent
Item
compromised ability to give informed consent (defined per clinical judgment).
boolean
C0085732 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0021430 (UMLS CUI [1,3])
Tumor type Unknown | Tumor type Mutant RAS
Item
unknown or mutant ras tumor type
boolean
C4263544 (UMLS CUI [1,1])
C0439673 (UMLS CUI [1,2])
C4263544 (UMLS CUI [2,1])
C4331205 (UMLS CUI [2,2])

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video